Table 4.
Effect of any rhG-CSF use on metastasis following postoperative chemotherapy in NSCLC by follow-up 1, 2 and 3 year
| Follow-up 1 Year | Follow-up 2 Year | Follow-up 3 Year | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total, n | Events, n (%) | Adjusted I | Adjusted II | Events, n (%) | Adjusted I | Adjust II | Events, n (%) | Adjusted I | Adjusted II | |
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | |||||
| rhG-CSF | ||||||||||
| No rhG-CSF | 61 | 4 (6.56%) | 1 | 1 | 8 (13.11%) | 1 | 1 | 12 (19.67%) | 1 | 1 |
| rhG-CSF | 246 | 54 (21.95%) | 4.02 (1.45,11.11) | 4.44 (1.54,12.79) | 80 (32.52%) | 3.17 (1.53, 6.58) | 2.91 (1.34, 6.29) | 101 (41.05%) | 2.66 (1.45, 4.86) | 2.53 (1.32, 4.82) |
| Doseage (μg) | ||||||||||
| 0 | 61 | 4 (6.56%) | 1 | 1 | 8 (13.11%) | 1 | 1 | 12 (19.67%) | 1 | 1 |
| ≤ 500 | 96 | 19 (19.79%) | 3.74 (1.27, 11.01) | 4.09 (1.36, 12.34) | 32 (33.33%) | 3.37 (1.55, 7.33) | 3.13 (1.40, 7.00) | 41 (42.71%) | 2.91 (1.52, 5.57) | 2.76 (1.41, 5.43) |
| 500–1000 | 85 | 20 (23.53%) | 4.36 (1.49, 12.82) | 5.36 (1.70, 16.89) | 26 (30.59%) | 3.00 (1.35, 6.65) | 2.79 (1.18, 6.64) | 32 (37.65%) | 2.47 (1.29, 4.82) | 2.50 (1.20, 5.20) |
| 1000–1500 | 32 | 6 (18.75%) | 2.97 (0.84, 10.58) | 3.57 (0.96, 13.27) | 10 (31.25%) | 2.53 (0.99, 6.47) | 2.30 (0.87, 6.06) | 13 (40.63%) | 2.06 (0.93, 4.57) | 1.88 (0.82, 4.31) |
| > 1500 | 33 | 9 (27.27%) | 5.21 (1.59, 17.01) | 7.18 (1.96, 26.26) | 12 (36.36%) | 3.88 (1.58, 9.54) | 3.88 (1.42, 10.59) | 15 (45.45%) | 3.18 (1.48, 6.82) | 3.12 (1.32, 7.38) |
| p for trend | 0.04 | 0.03 | 0.05 | 0.16 | 0.08 | 0.23 | ||||
| Dose density (μg/day) | ||||||||||
| 0 | 67 | 5 (7.46%) | 1 | 1 | 10 (14.93%) | 1 | 1 | 15 (22.39%) | 1 | 1 |
| < 15 | 71 | 13 (18.31%) | 2.52 (0.90, 7.08) | 2.91 (0.97, 8.75) | 20 (28.17%) | 1.97 (0.92, 4.23) | 1.89 (0.83, 4.3) | 29 (40.85%) | 1.83 (0.98, 3.42) | 1.79 (0.90, 3.55) |
| 15–60 | 89 | 21 (13.16%) | 3.65 (1.37, 9.71) | 3.74 (1.31, 10.67) | 28 (31.46%) | 2.63 (1.27, 5.42) | 2.16 (0.98, 4.76) | 31 (34.83%) | 1.87 (1.01, 3.48) | 1.59 (0.80, 3.15) |
| 60–200 | 38 | 5 (13.16%) | 2.25 (0.65, 7.84) | 1.97 (0.55, 7.15) | 11 (28.95%) | 2.48 (1.05, 5.88) | 1.83 (0.74, 4.51) | 16 (42.11%) | 2.51 (1.23, 5.12) | 1.88 (0.89, 3.97) |
| ≥ 200 | 42 | 14 (33.33%) | 6.13 (2.19, 17.11) | 5.88 (2.06, 16.85) | 19 (45.24%) | 4.97 (2.3, 10.75) | 4.18 (1.88, 9.29) | 22 (52.38%) | 4.09 (2.11, 7.94) | 3.38 (1.69, 6.74) |
| p for trend | < 0.001 | 0.01 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | ||||
Adjusted I model adjust for: Age; Sex; Weight; Smoking
Adjusted II model adjust for: Age; Sex; Weight; Smoking; Histopathology; Differentiation; Complications; Pathological stage; Chemotherapy; Number of chemotherapy; Myelosuppression; Fever; Antibiotic
HR Hazard ratio, CI Confidence interval, rhG-CSF Recombinant human granulocyte-colony stimulating factor